| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Country's Decision or any other Communication
Record information and status
Record ID
116061
Status
Published
Date of creation
2021-05-03 09:13 UTC (jnjagi@biosafetykenya.go.ke)
Date of publication
2021-05-17 11:45 UTC (jmuchiri@biosafetykenya.go.ke)

General information
Country submitting the decision or communication
  • Kenya
Competent National Authority(ies) responsible for the decision or communication
National Biosafety Authority
NACOSTI Building, Loresho, off Waiyaki Way
Nairobi, Nairobi
Kenya, 28251--00100
Phone:(+254) (20) (2678667)
Email:info@biosafetykenya.go.ke
Url:National Biosafety Office - Kenya
Title / Reference number of the decision or communication
Approval to Conduct Confined Field trial of a Novel Rift Valley Fever Vaccine in Sheep, Goats, Cattle and Camels 
Date of the decision
2016-11-25
Is the decision taken prior to entry into force of the Protocol?
No
Is this an amendment to a previous decision / communication?
No
Decision or communication details
Subject(s) of the decision
  • Decision on LMOs for intentional introduction into the environment (according to Article 10 or domestic regulatory framework)
Was the decision triggered by a request for a transboundary movement of LMOs into the country?
No
Does the decision apply to transboundary movements of LMO(s) into the country?
No
Importer’s or Applicant’s contact details
Dr. George Warimwe
Principal Scientist
International Livestock Research Institute (ILRI) /The Jenner Institute, University of Oxford, United Kingdom
Nairobi
Kenya
Phone:+1865617622
Fax:+1865617608
Email:gwarimwe@kemri-wellcome.org
Result of the decision
  • Approval of the import and/or use of the LMO(s) with conditions
Conditions
For the purposes of conducting confined field trials (CFTs) only.
Reasons
The application is for Contained Use
Does the decision involve field trials?
Yes
Does the decision involve commercial release?
No
LMO identification
Rift Valley Fever Virus DIVA vaccine
Dr. George Warimwe Production of medical or pharmaceutical compounds (human or animal) - Vaccines, Antibodies and antigens
Risk assessment
Summary risk assessment report on the application for Confined Field Trial of a novel Rift Valley Fever Vaccine in sheep, goats, cattle and camels
Rift Valley Fever Virus DIVA vaccine
Dr. George Warimwe

Production of medical or pharmaceutical compounds (human or animal) - Vaccines, Antibodies and antigens
Decision document